PRO Development for ANCA Associated Vasculitis
NCT01729624 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50
Last updated 2015-05-28
Summary
A qualitative study using interviews with patients who have antineutrophil cytoplasm antibody (ANCA) associated vasculitis, to develop a patient reported outcome (PRO)measure
Conditions
- Wegener Granulomatosis
- Microscopic Polyangiitis
- Churg-Strauss Syndrome
Sponsors & Collaborators
-
University of Oxford
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2012-09-30
- Primary Completion
- 2015-08-31
- Completion
- 2015-08-31
Countries
- United Kingdom
Study Locations
More Related Trials
-
Obinutuzumab for Remission Induction in Patients With Relapsing PR3-ANCA Granulomatosis With Polyangiitis
NCT06940661 ·Status: RECRUITING ·Phase: PHASE2
-
Evaluation of Anti-neutrophil Cytoplasm Antibodies Test
NCT04719715 ·Status: UNKNOWN
-
Pilot Study of Short-Course Glucocorticoids and Rituximab for Treatment of ANCA-Associated Vasculitis
NCT02169219 ·Status: COMPLETED ·Phase: PHASE4
-
Exploring Durable Remission With Rituximab in Antineutrophil Cytoplasmic Antibody(ANCA)-Associated Vasculitis
NCT03942887 ·Status: RECRUITING ·Phase: PHASE3
-
Defining Immune Tolerance in ANCA-associated Vasculitis (AAV)
NCT01934504 ·Status: TERMINATED
-
Evaluate the Remission MAINtenance Using Extended Administration of Prednisone in Systemic Anti-neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis.
NCT03290456 ·Status: RECRUITING ·Phase: NA
-
A Study to Evaluate the Safety and Efficacy of CCX168 in Subjects With ANCA-Associated Vasculitis
NCT01363388 ·Status: COMPLETED ·Phase: PHASE2
-
Tailoring Maintenance Therapy to Cluster of Differentiation 5 Positive (CD5+) Regulatory B Cell Recovery in ANCA Vasculitis
NCT03906227 ·Status: TERMINATED ·Phase: NA
-
Hydroxychloroquine in ANCA Vasculitis Evaluation
NCT04316494 ·Status: TERMINATED ·Phase: PHASE4
-
A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis
NCT06072482 ·Status: RECRUITING ·Phase: PHASE4
-
Pharmacokinetic Study of Rituximab Induction Regimen in ANCA-associated Vasculitis
NCT02474888 ·Status: TERMINATED
-
Efficacy Study of Two Treatments in the Remission of Vasculitis
NCT00748644 ·Status: COMPLETED ·Phase: PHASE3
-
Intravenous Immunoglobulin After Relapse in Vasculitis
NCT00307658 ·Status: TERMINATED ·Phase: PHASE3
-
Biosimilars of Rituximab in ANCA-associated Vasculitis Compared to the Originator
NCT05716334 ·Status: COMPLETED
-
Plasma Exchange and Glucocorticoids for Treatment of Anti-Neutrophil Cytoplasm Antibody (ANCA) - Associated Vasculitis
NCT00987389 ·Status: COMPLETED ·Phase: PHASE3
-
Rituximab and Belimumab Combination Therapy in PR3 Vasculitis
NCT03967925 ·Status: UNKNOWN ·Phase: PHASE2
-
Comparison Study of Two Rituximab Regimens in the Remission of ANCA Associated Vasculitis
NCT01731561 ·Status: COMPLETED ·Phase: PHASE3
-
Iptacopan in Patients With ANCA Associated Vasculitis
NCT06388941 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Abatacept in ANCA Associated Vasculitis
NCT00482066 ·Status: TERMINATED ·Phase: PHASE2
-
Clinical Relevance of Anti-Neutrophil Cytoplasm Antibody (ANCA)in Hospitalized Patients
NCT01238003 ·Status: UNKNOWN
-
Low-dose Glucocorticoid Vasculitis Induction Study
NCT02198248 ·Status: UNKNOWN ·Phase: PHASE4
-
One-Time DNA Study for Vasculitis
NCT01241305 ·Status: RECRUITING
-
Occupational and Environmental Origins of ANCA Vasculitis: Contribution of Data From the National Network for Vigilance and Prevention of Occupational Pathologies (RNV3P)
NCT05416723 ·Status: UNKNOWN
-
(68)Ga-FAPI PET/CT in Patients With ANCA-associated Vasculitis
NCT07151521 ·Status: RECRUITING
-
Maintenance of ANCA Vasculitis Remission by Intermittent Rituximab Dosing
NCT02749292 ·Status: TERMINATED ·Phase: PHASE4